AVICOVID-3 Inhaled Use of Zyesami for Treatment of Severe COVID-19

Conditions:   SARS-CoV 2;   COVID;   ARDS;   ALI;   Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS);   Dyspnea Interventions:   Drug: ZYESAMI™ (aviptadil acetate);   Drug: Placebo;   Device: Nebulized administration of ZYESAMI™ or Placebo Sponsors:   NeuroRx, Inc.;   Cromos, LLC, Tbilisi, Georgia;   Lugar Research Center, Tbilisi, Georgia Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials